Silexion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2013	FY 2012
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Cash & Equivalents	1.19	4.6	0.79	1.6
Cash & Short-Term Investments	1.19	4.6	0.79	1.6
Cash Growth	-74.17%	483.12%	-50.69%	-
Other Receivables	-	-	0.09	0.16
Receivables	-	-	0.09	0.16
Prepaid Expenses	0.97	0.34	0.01	-
Restricted Cash	0.04	0.03	-	-
Other Current Assets	0.06	0.02	0.04	0.03
Total Current Assets	2.25	4.98	0.93	1.79
Property, Plant & Equipment	0.56	0.25	0.01	0.01
Other Long-Term Assets	0.05	0.03	-	-
Total Assets	2.86	5.26	0.94	1.8
Accounts Payable	0.93	0.32	0.1	0.08
Accrued Expenses	1.43	1.57	0.14	0.09
Short-Term Debt	1	-	-	-
Current Portion of Leases	0.16	0.11	-	-
Other Current Liabilities	0	0.2	-	-
Total Current Liabilities	3.52	2.2	0.24	0.17
Long-Term Debt	2.96	-	-	-
Long-Term Leases	0.37	0.06	-	-
Total Liabilities	6.85	2.26	0.24	0.17
Common Stock	0	-	-	-
Additional Paid-In Capital	39.26	11.34	5.16	4.74
Retained Earnings	-43.25	-26.81	-4.47	-3.11
Total Common Equity	-3.99	-15.48	0.7	1.63
Minority Interest	-	3.42	-	-
Shareholders' Equity	-3.99	3	0.7	1.63
Total Liabilities & Equity	2.86	5.26	0.94	1.8
Total Debt	4.49	0.17	-	-
Net Cash (Debt)	-3.3	4.42	0.79	1.6
Net Cash Growth	-	461.42%	-50.69%	-
Net Cash Per Share	-79.44	-	-	-
Filing Date Shares Outstanding	0.56	-	-	-
Total Common Shares Outstanding	0.12	-	-	-
Working Capital	-1.27	2.78	0.69	1.62
Book Value Per Share	-32.37	-	-	-
Tangible Book Value	-3.99	-15.48	0.7	1.63
Tangible Book Value Per Share	-32.37	-	-	-
Machinery	0.1	0.08	0.02	0.01
Leasehold Improvements	-	0.06	-	-

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q